Prognostic value of vascular endothelial growth factor and its receptor Flt‐1 in squamous cell lung cancer

M Volm, R Koomägi, J Mattern - International journal of cancer, 1997 - Wiley Online Library
Tumor specimens from 109 patients with previously untreated squamous cell lung carcinomas
were analyzed immunohistologically for the expression of vascular endothelial growth …

Tissue‐factor expression in human non‐small‐cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis

R Koomägi, M Volm - International journal of cancer, 1998 - Wiley Online Library
Reet KOOMAgi and Manfred VOLM* … In an earlier study, we demonstrated an inverse
correlation between resistance-related proteins and microvessel density (Koomägi et al., 1995), …

Expression of FAS (CD95/APO‐1) and FAS ligand in lung cancer, its prognostic and predictive relevance

R Koomägi, M Volm - International journal of cancer, 1999 - Wiley Online Library
In order to examine whether or not the expression of the apoptosis‐related receptor Fas (CD‐95/APO‐1)
and its ligand (FasL) has relevance for patient survival, immunohistochemistry …

Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain …

R Koomagi, F Zintl, A Sauerbrey, M Volm - Clinical Cancer Research, 2001 - AACR
Purpose: Overexpression of vascular endothelial growth factor (VEGF) is associated with
increased angiogenesis, growth, and metastasis in solid tumors, but to date the significance of …

Biological characterization of subgroups of squamous cell lung carcinomas

J Mattern, R Koomägi, M Volm - Clinical cancer research, 1999 - AACR
Recently, Pezzella et al. (Am. J. Pathol., 1997, 151: 1417–1423, 1997) reported on a
subgroup of non-small cell lung carcinomas that had no morphological evidence of …

Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients

M Volm, R Koomägi, J Mattern, T Efferth - Clinical cancer research, 2002 - AACR
Purpose: Non-small cell lung cancer (NSCLC) is usually associated with a poor prognosis.
Some patients survive their disease, and the underlying molecular mechanisms are still …

Prediction of drug sensitivity and resistance of cancer by protein expression profiling

M Volm, R Koomagi, T Efferth - Cancer genomics & proteomics, 2004 - cgp.iiarjournals.org
Although the statistical probability of therapeutic success is known for larger groups of cancer
patients, the clinical response to chemotherapy of the individual patient remains uncertain. …

Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran

…, A Allameh, P Mirbod, HJ Groene, R Koomagi… - Cancer Research, 2001 - AACR
Over 15,000 human tumor p53 mutations have been recorded in the scientific literature,
including over 700 mutations in esophageal tumors. There are no data on p53 mutations in …

Angiostatin expression in non-small cell lung cancer

M Volm, J Mattern, R Koomägi - Clinical cancer research, 2000 - AACR
Angiostatin, a potent inhibitor of angiogenesis, tumor growth, and metastasis, was examined
in a panel of human lung cancer cell lines with Western blot analysis and in 143 primary non…

Prognostic implications of cyclins (D1, E, A), cyclin‐dependent kinases (CDK2, CDK4) and tumor‐suppressor genes (pRb, p16INK4A) in childhood acute …

M Volm, R Koomägi, G Stammler… - … journal of cancer, 1997 - Wiley Online Library
Immunohistochemistry was used to analyze samples of 40 newly diagnosed childhood
acute lymphoblastic leukemias (ALL) for their expression of cyclins (D1, E, A), cyclin‐dependent …